INmune Bio, Inc. (NASDAQ:INMB) Receives $8.00 Consensus PT from Analysts

INmune Bio, Inc. (NASDAQ:INMB) has been given an average recommendation of “Hold” by the six ratings firms that are covering the firm, MarketBeat reports. Two research analysts have rated the stock with a sell rating, two have given a hold rating, one has given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $8.00.

A number of research analysts recently commented on INMB shares. Wall Street Zen upgraded INmune Bio from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Lucid Cap Mkts upgraded INmune Bio from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Jain Global LLC bought a new position in INmune Bio in the fourth quarter valued at about $66,000. Charles Schwab Investment Management Inc. grew its position in INmune Bio by 20.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after acquiring an additional 8,427 shares during the last quarter. Wells Fargo & Company MN grew its position in INmune Bio by 79.0% in the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after acquiring an additional 10,970 shares during the last quarter. Bank of Montreal Can bought a new position in INmune Bio in the fourth quarter valued at about $41,000. Finally, Goldman Sachs Group Inc. grew its position in INmune Bio by 269.0% in the fourth quarter. Goldman Sachs Group Inc. now owns 56,477 shares of the company’s stock valued at $88,000 after acquiring an additional 41,173 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Performance

INMB opened at $1.29 on Thursday. INmune Bio has a fifty-two week low of $1.09 and a fifty-two week high of $11.64. The company has a market capitalization of $34.29 million, a P/E ratio of -0.68 and a beta of 0.88. The stock has a fifty day moving average of $1.34 and a 200-day moving average of $1.61.

INmune Bio (NASDAQ:INMB) last posted its earnings results on Monday, March 30th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09. On average, equities research analysts predict that INmune Bio will post -2.24 earnings per share for the current fiscal year.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.